Amy McTague
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amy McTague has a total of 502 co-authors. Here are the top co-authors by number of shared publications:
- Judith Helen Cross
University College London National Institute for Health and Care Research Biomedical Research Centres Great Ormond Street Institute of Child Health London UK
9 shared publications - Manju Ann Kurian
Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, Great Ormond Street–Institute of Child Health (GOS-ICH), University College London (UCL)
6 shared publications - Ingrid Eileen Scheffer
Epilepsy Research Centre University of Melbourne, Austin Health Heidelberg Victoria Australia
5 shared publications - Sophie Adler
School of Biomedical Engineering & Imaging Sciences, King’s College London, UK
5 shared publications - Aswin Chari
Department of Neurosurgery, Great Ormond Street Hospital, London, UK
4 shared publications - John Booth
Innovation and Virtual Environments, NIHR Great Ormond Street Hospital Biomedical Research Centre and GOSH Data Research, London, UK
4 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1556-1569
Genetic testing practices across European epilepsy centers: An ERN EpiCARE survey
Objective: Genetic testing plays an increasing role in the diagnostic pathway for rare and complex epilepsies. However, significant heterogeneity persists in access, implementation, and interpretation across Europe. This study aimed to assess genetic testing practices, accessibility, and challenges across expert epilepsy centers within the European Reference Network for Rare and Complex Epilepsies (ERN EpiCARE) and to identify key challenges and areas for harmonization. Methods: A cross‐sectional survey was developed by the ERN EpiCARE Clinical Genetics Working Group and distributed to 50 EpiCARE member centers across 27 European countries. The questionnaire collected quantitative and qualitative information on available genetic testing modalities, turnaround times, use of rapid testing, multidisciplinary team (MDT) organization, genetic counseling practices, and perceived challenges. Survey findings were complemented by a structured discussion held during the ERN EpiCARE General Assembly. Results: Responses were received from 46 centers (51 responses). Most centers reported access to genetic testing, predominantly through in‐house facilities. Whole‐exome sequencing was available in 85% of centers, and gene panels were available in 78%. Whole‐genome sequencing was available in 59% of centers, frequently restricted to research or performed externally. Turnaround times for standard genetic testing were most commonly between 1 and 6 months. Genetic testing strategies varied by epilepsy subtype, with gene panels most frequently used as first‐tier testing, and exome sequencing preferentially applied in developmental and epileptic encephalopathies. Considerable heterogeneity was observed in MDT organization, access to genetic counseling, reimbursement, data‐sharing and registry infrastructures. Significance: Although genetic testing is widely available across ERN EpiCARE centers, substantial disparities persist in its organization, accessibility, and implementation. Addressing these gaps through strengthened multidisciplinary collaboration, harmonized diagnostic strategies, and enhanced European‐level coordination will be essential to ensure equitable access to high‐quality genetic care for individuals with epilepsy. Plain Language Summary: Genetic testing is increasingly integrated in the diagnostic pathway for rare and complex epilepsies and treatment decisions. An ERN EpiCARE survey assessed how genetic testing is implemented across specialist epilepsy centers in Europe and identified persistent organizational, financial, and clinical barriers. Although most centers had access to advanced genomic testing, important differences were identified in access, reimbursement, turnaround times, and multidisciplinary expertise. European collaboration and harmonized practices are needed to support equitable access to high‐quality genetic care for people living with epilepsy.
- 2 September 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (5) , 1556-1569
Open AccessGenetic testing practices across European epilepsy centers: An ERN EpiCARE survey
Objective: Genetic testing plays an increasing role in the diagnostic pathway for rare and complex epilepsies. However, significant heterogeneity persists in access, implementation, and interpretation across Europe. This study aimed to assess genetic testing practices, accessibility, and challenges across expert epilepsy centers within the European Reference Network for Rare and Complex Epilepsies (ERN EpiCARE) and to identify key challenges and areas for harmonization. Methods: A cross‐sectional survey was developed by the ERN EpiCARE Clinical Genetics Working Group and distributed to 50 EpiCARE member centers across 27 European countries. The questionnaire collected quantitative and qualitative information on available genetic testing modalities, turnaround times, use of rapid testing, multidisciplinary team (MDT) organization, genetic counseling practices, and perceived challenges. Survey findings were complemented by a structured discussion held during the ERN EpiCARE General Assembly. Results: Responses were received from 46 centers (51 responses). Most centers reported access to genetic testing, predominantly through in‐house facilities. Whole‐exome sequencing was available in 85% of centers, and gene panels were available in 78%. Whole‐genome sequencing was available in 59% of centers, frequently restricted to research or performed externally. Turnaround times for standard genetic testing were most commonly between 1 and 6 months. Genetic testing strategies varied by epilepsy subtype, with gene panels most frequently used as first‐tier testing, and exome sequencing preferentially applied in developmental and epileptic encephalopathies. Considerable heterogeneity was observed in MDT organization, access to genetic counseling, reimbursement, data‐sharing and registry infrastructures. Significance: Although genetic testing is widely available across ERN EpiCARE centers, substantial disparities persist in its organization, accessibility, and implementation. Addressing these gaps through strengthened multidisciplinary collaboration, harmonized diagnostic strategies, and enhanced European‐level coordination will be essential to ensure equitable access to high‐quality genetic care for individuals with epilepsy. Plain Language Summary: Genetic testing is increasingly integrated in the diagnostic pathway for rare and complex epilepsies and treatment decisions. An ERN EpiCARE survey assessed how genetic testing is implemented across specialist epilepsy centers in Europe and identified persistent organizational, financial, and clinical barriers. Although most centers had access to advanced genomic testing, important differences were identified in access, reimbursement, turnaround times, and multidisciplinary expertise. European collaboration and harmonized practices are needed to support equitable access to high‐quality genetic care for people living with epilepsy.
- Open Access
- 25 May 2026
- Published by Springer Nature in npj Genomic Medicine
- Vol. 11 (1)
Expanding the phenotypic spectrum of FGF12-epilepsy—does prompt precision therapy affect outcomes?
Fibroblast growth factor-12 ( FGF12 ) variants have been associated with developmental and epileptic encephalopathy (DEE) with evidence of modulation of voltage-gated sodium channels Na v 1.2 and Na v 1.6. We aim to expand the phenotypic spectrum of FGF12- related epilepsy with emphasis on precision therapy. We describe 12 patients: eight with neonatal onset seizures with the recurrent p.Arg52His (c.155 G > A) variant, two with a previously unreported p.Glu153Gly (c.458 A > G) variant, one with a p.Gly50Ser (c.148 G > A) variant, and one with a de novo whole-gene duplication. Atypical absence seizures were present in 5/12 patients. Brain MRI was normal in 10/12; one patient’s MRIs showed progressive cerebellar atrophy, and one patient’s MRI showed a hemispheric infarct. 8 patients promptly started on sodium channel blockers became seizure-free with good developmental outcomes while 4 developed DEE. In summary, we expand the phenotypic spectrum of FGF12- related epilepsy and discuss the role of early precision therapy in developmental and epilepsy outcomes.
- 25 May 2026
- Published by Springer Nature in npj Genomic Medicine
- Vol. 11 (1)
Open AccessExpanding the phenotypic spectrum of FGF12-epilepsy—does prompt precision therapy affect outcomes?
Fibroblast growth factor-12 ( FGF12 ) variants have been associated with developmental and epileptic encephalopathy (DEE) with evidence of modulation of voltage-gated sodium channels Na v 1.2 and Na v 1.6. We aim to expand the phenotypic spectrum of FGF12- related epilepsy with emphasis on precision therapy. We describe 12 patients: eight with neonatal onset seizures with the recurrent p.Arg52His (c.155 G > A) variant, two with a previously unreported p.Glu153Gly (c.458 A > G) variant, one with a p.Gly50Ser (c.148 G > A) variant, and one with a de novo whole-gene duplication. Atypical absence seizures were present in 5/12 patients. Brain MRI was normal in 10/12; one patient’s MRIs showed progressive cerebellar atrophy, and one patient’s MRI showed a hemispheric infarct. 8 patients promptly started on sodium channel blockers became seizure-free with good developmental outcomes while 4 developed DEE. In summary, we expand the phenotypic spectrum of FGF12- related epilepsy and discuss the role of early precision therapy in developmental and epilepsy outcomes.
- 17 April 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 139, 70-74
Uridine-responsive epileptic encephalopathy: Precision treatment across the age spectrum – a case series
- 17 April 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 139, 70-74
Uridine-responsive epileptic encephalopathy: Precision treatment across the age spectrum – a case series
- Open Access
Predictive value of seizure onset for gross motor dysfunction in individuals with pathogenic GABRB2 and GABRB3 variants
Objective: Pathogenic variants in γ‐aminobutyric acid type A (GABA A ) receptor genes have been associated with a wide spectrum of neurological disorders. We aimed to delineate the clinical trajectories associated with gain‐of‐function (GoF) and loss‐of‐function (LoF) variants in GABRB2 and GABRB3 , and to develop a risk‐prediction model for gross motor dysfunction based on age at seizure onset. Methods: Clinical data, including seizure onset, epilepsy syndromes, cognitive outcomes, and gross motor function classification system (GMFCS), were collected through direct interviews, physician reports, and literature review. Kruskal–Wallis, Mantel–Cox and non‐parametric analysis of variance (ANOVA) with Dunn's corrected post hoc tests were used for statistical comparisons. A logistic ordinal regression model was developed to predict GMFCS outcomes based on age at seizure onset. Results: We analyzed a cohort of 117 individuals with pathogenic GABRB2 ( n = 49) and GABRB3 ( n = 68) variants. Fifty‐three individuals carried GoF variants and 64 carried LoF variants. The GoF group was associated with earlier seizure onset, higher seizure frequency, and lower rates of seizure freedom. Gross motor dysfunction was markedly worse in the GoF group, with 64% classified as GMFCS IV or V (non‐ambulation), compared to 7.5% in the LoF group. An inverse correlation was found between age at seizure onset and GMFCS severity in the GoF, but not the LOF group. The risk model predicted a >90% likelihood of non‐ambulation for individuals with GoF variants and seizure onset before 1 month of age, decreasing to ~35% with seizure onset after 20 months. Significance: We found a clear genotype–phenotype correlation in GABRB2‐ and GABRB3 ‐related disorders, demonstrating that GoF variants are associated with a more severe neurodevelopmental trajectory. The age at seizure onset serves as a biomarker for predicting motor outcomes in individuals with GoF variants. These findings provide guidance regarding prognosis, need for early intervention, and data for comparison of efficacy in targeted therapeutic interventions for GABA A receptor–related disorders.
Open AccessPredictive value of seizure onset for gross motor dysfunction in individuals with pathogenic GABRB2 and GABRB3 variants
Objective: Pathogenic variants in γ‐aminobutyric acid type A (GABA A ) receptor genes have been associated with a wide spectrum of neurological disorders. We aimed to delineate the clinical trajectories associated with gain‐of‐function (GoF) and loss‐of‐function (LoF) variants in GABRB2 and GABRB3 , and to develop a risk‐prediction model for gross motor dysfunction based on age at seizure onset. Methods: Clinical data, including seizure onset, epilepsy syndromes, cognitive outcomes, and gross motor function classification system (GMFCS), were collected through direct interviews, physician reports, and literature review. Kruskal–Wallis, Mantel–Cox and non‐parametric analysis of variance (ANOVA) with Dunn's corrected post hoc tests were used for statistical comparisons. A logistic ordinal regression model was developed to predict GMFCS outcomes based on age at seizure onset. Results: We analyzed a cohort of 117 individuals with pathogenic GABRB2 ( n = 49) and GABRB3 ( n = 68) variants. Fifty‐three individuals carried GoF variants and 64 carried LoF variants. The GoF group was associated with earlier seizure onset, higher seizure frequency, and lower rates of seizure freedom. Gross motor dysfunction was markedly worse in the GoF group, with 64% classified as GMFCS IV or V (non‐ambulation), compared to 7.5% in the LoF group. An inverse correlation was found between age at seizure onset and GMFCS severity in the GoF, but not the LOF group. The risk model predicted a >90% likelihood of non‐ambulation for individuals with GoF variants and seizure onset before 1 month of age, decreasing to ~35% with seizure onset after 20 months. Significance: We found a clear genotype–phenotype correlation in GABRB2‐ and GABRB3 ‐related disorders, demonstrating that GoF variants are associated with a more severe neurodevelopmental trajectory. The age at seizure onset serves as a biomarker for predicting motor outcomes in individuals with GoF variants. These findings provide guidance regarding prognosis, need for early intervention, and data for comparison of efficacy in targeted therapeutic interventions for GABA A receptor–related disorders.
- Open Access
- 5 January 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (1) , 291-321
Areas of research priorities in epilepsy: A position paper of the European Reference Network for Rare and Complex Epilepsies, EpiCARE
Objective: To define and articulate research priorities in epilepsy identified by the European Reference Network for Rare and Complex Epilepsies (ERN EpiCARE), addressing key unmet needs across the spectrum of rare and complex epilepsies. Methods: This position paper was developed through a structured collaborative process involving patient associations and experts from EpiCARE Working Groups, the EpiCARE Executive Committee, and its Research Council. Contributions were integrated and harmonized to establish a shared set of research priorities reflecting clinical, translational, and methodological perspectives. Results: Six priority areas were identified and examined: prevention of epileptogenesis and disease‐modifying challenges; genetics and targeted therapies; improved surgical decision‐making; innovative trial designs and outcome measures; artificial intelligence for diagnosis and prediction; understanding and preventing comorbidities and mortality. For each priority, the paper discusses the current state of research, identifies challenges, and proposes strategic directions for future investigations. Significance: This position paper provides a strategic framework to guide future research efforts, inform prioritization by funders and policymakers, and foster coordinated collaboration across stakeholders. By advancing these priorities, the epilepsy research community aims to improve patient care, reduce health disparities, and develop innovative solutions to address the complexities of epilepsy. Plain Language Summary: This position paper, developed by the European Reference Network for Rare and Complex Epilepsies (EpiCARE) in collaboration with its Patient Advocacy Group, defines six areas of research priorities in epilepsy. Each section describes key challenges, current knowledge, and areas for improvement. They focus on preventing epilepsy, developing targeted therapies, improving surgery and clinical trials, using artificial intelligence to support diagnosis, and addressing comorbidities such as cognition, sleep, and overall health. Each provides a roadmap for clinicians and researchers to guide their research projects within their areas of expertise. Collectively, these priorities converge on actions for improving diagnosis, treatment, and patient outcomes through European collaboration and sustainable research efforts.
- 5 January 2026
- Published by Wiley in Epilepsia Open
- Vol. 11 (1) , 291-321
Open AccessAreas of research priorities in epilepsy: A position paper of the European Reference Network for Rare and Complex Epilepsies, EpiCARE
Objective: To define and articulate research priorities in epilepsy identified by the European Reference Network for Rare and Complex Epilepsies (ERN EpiCARE), addressing key unmet needs across the spectrum of rare and complex epilepsies. Methods: This position paper was developed through a structured collaborative process involving patient associations and experts from EpiCARE Working Groups, the EpiCARE Executive Committee, and its Research Council. Contributions were integrated and harmonized to establish a shared set of research priorities reflecting clinical, translational, and methodological perspectives. Results: Six priority areas were identified and examined: prevention of epileptogenesis and disease‐modifying challenges; genetics and targeted therapies; improved surgical decision‐making; innovative trial designs and outcome measures; artificial intelligence for diagnosis and prediction; understanding and preventing comorbidities and mortality. For each priority, the paper discusses the current state of research, identifies challenges, and proposes strategic directions for future investigations. Significance: This position paper provides a strategic framework to guide future research efforts, inform prioritization by funders and policymakers, and foster coordinated collaboration across stakeholders. By advancing these priorities, the epilepsy research community aims to improve patient care, reduce health disparities, and develop innovative solutions to address the complexities of epilepsy. Plain Language Summary: This position paper, developed by the European Reference Network for Rare and Complex Epilepsies (EpiCARE) in collaboration with its Patient Advocacy Group, defines six areas of research priorities in epilepsy. Each section describes key challenges, current knowledge, and areas for improvement. They focus on preventing epilepsy, developing targeted therapies, improving surgery and clinical trials, using artificial intelligence to support diagnosis, and addressing comorbidities such as cognition, sleep, and overall health. Each provides a roadmap for clinicians and researchers to guide their research projects within their areas of expertise. Collectively, these priorities converge on actions for improving diagnosis, treatment, and patient outcomes through European collaboration and sustainable research efforts.
- Open Access
- 9 May 2025
- Published by Springer Nature in Research Square
Prenatal sodium channel dysfunction in Dravet syndrome alters cortical development
Neurodevelopmental disorders associated with epilepsy are typically linked to postnatal dysfunction of synaptic proteins and ion channels, yet increasing evidence suggests a role for these proteins before birth. The voltage-gated sodium channel Nav1.1, encoded by SCN1A, is well studied postnatally. SCN1A mutations result in a broad range of neurological phenotypes including developmental and epileptic encephalopathies (DEEs including Dravet syndrome, DS) and fetal lethality. Here, we investigated the role of SCN1A dysfunction in early corticogenesis. By integrating data from DS patient-derived forebrain models, a DS mouse model, and DS post-mortem tissue, we report altered G2/M cell cycle transition, with a shift towards earlier neurogenic fate commitment. These changes lead to altered cortical specification at birth and throughout life. The early developmental roles of Nav1.1 complement the well-known postnatal roles in neuronal excitability. These discoveries reveal new insights into the DS pathogenesis and a new non-canonical role for Nav1.1 in early corticogenesis.
- 9 May 2025
- Published by Springer Nature in Research Square
Open AccessPrenatal sodium channel dysfunction in Dravet syndrome alters cortical development
Neurodevelopmental disorders associated with epilepsy are typically linked to postnatal dysfunction of synaptic proteins and ion channels, yet increasing evidence suggests a role for these proteins before birth. The voltage-gated sodium channel Nav1.1, encoded by SCN1A, is well studied postnatally. SCN1A mutations result in a broad range of neurological phenotypes including developmental and epileptic encephalopathies (DEEs including Dravet syndrome, DS) and fetal lethality. Here, we investigated the role of SCN1A dysfunction in early corticogenesis. By integrating data from DS patient-derived forebrain models, a DS mouse model, and DS post-mortem tissue, we report altered G2/M cell cycle transition, with a shift towards earlier neurogenic fate commitment. These changes lead to altered cortical specification at birth and throughout life. The early developmental roles of Nav1.1 complement the well-known postnatal roles in neuronal excitability. These discoveries reveal new insights into the DS pathogenesis and a new non-canonical role for Nav1.1 in early corticogenesis.
- Open Access
- 25 March 2025
- Published by SAGE Publications in Epilepsy Currents
- Vol. 25 (3) , 229-235
Merritt-Putnam Symposium | Developmental and Epileptic Encephalopathies—Current Concepts and Novel Approaches
Developmental and epileptic encephalopathies (DEEs) are among the most severe and difficult to treat epilepsies. Two broad strategies for understanding the etiology and impacts of DEEs include genetic and complex adaptive systems approaches. This review, inspired by the 2024 Merritt-Putnam Symposium, describes current perspectives of DEE, identifies limitations of current views, and discusses potential novel ways forward. First, we discuss the rationale for a reevaluation of the role of seizures in the pathogenesis of cognitive and behavioral impairments in DEE. Second, we discuss newly emerging methods employing neural organoids to study brain development and DEE in vitro. Third, we present recent precision therapy approaches for the clinical treatment of DEE. Lastly, we discuss computational systems approaches to understanding the genetic landscape of DEE. The severe and multifaceted impacts of DEE and associated comorbidities underscore the necessity of novel interdisciplinary approaches to produce an improved understanding of etiology and more effective treatment strategies.
- 25 March 2025
- Published by SAGE Publications in Epilepsy Currents
- Vol. 25 (3) , 229-235
Open AccessMerritt-Putnam Symposium | Developmental and Epileptic Encephalopathies—Current Concepts and Novel Approaches
Developmental and epileptic encephalopathies (DEEs) are among the most severe and difficult to treat epilepsies. Two broad strategies for understanding the etiology and impacts of DEEs include genetic and complex adaptive systems approaches. This review, inspired by the 2024 Merritt-Putnam Symposium, describes current perspectives of DEE, identifies limitations of current views, and discusses potential novel ways forward. First, we discuss the rationale for a reevaluation of the role of seizures in the pathogenesis of cognitive and behavioral impairments in DEE. Second, we discuss newly emerging methods employing neural organoids to study brain development and DEE in vitro. Third, we present recent precision therapy approaches for the clinical treatment of DEE. Lastly, we discuss computational systems approaches to understanding the genetic landscape of DEE. The severe and multifaceted impacts of DEE and associated comorbidities underscore the necessity of novel interdisciplinary approaches to produce an improved understanding of etiology and more effective treatment strategies.
- Top Cited PapersOpen Access
- 27 February 2025
- Published by Springer Nature in npj Genomic Medicine
- Vol. 10 (1) , 1-14
International Precision Child Health Partnership (IPCHiP): an initiative to accelerate discovery and improve outcomes in rare pediatric disease
Advances in genomic technologies have revolutionized the diagnosis of rare genetic diseases, leading to the emergence of precision therapies. However, there remains significant effort ahead to ensure the promise of precision medicine translates to improved outcomes. Here, we discuss the challenges in advancing precision child health and highlight how international collaborations such as the International Precision Child Health Partnership, which embed research into clinical care, can maximize benefits for children globally.
- 27 February 2025
- Published by Springer Nature in npj Genomic Medicine
- Vol. 10 (1) , 1-14
Top Cited PapersOpen AccessInternational Precision Child Health Partnership (IPCHiP): an initiative to accelerate discovery and improve outcomes in rare pediatric disease
Advances in genomic technologies have revolutionized the diagnosis of rare genetic diseases, leading to the emergence of precision therapies. However, there remains significant effort ahead to ensure the promise of precision medicine translates to improved outcomes. Here, we discuss the challenges in advancing precision child health and highlight how international collaborations such as the International Precision Child Health Partnership, which embed research into clinical care, can maximize benefits for children globally.
- Open Access
AAV9-mediated targeting of natural antisense transcript as a novel treatment for Dravet Syndrome
Dravet syndrome (DS) is a severe childhood onset developmental and epileptic encephalopathy which leads to life-long disability. Symptoms usually manifest in the first year of life and include prolonged severe seizures, developmental delay and severe intellectual disability. DS patients have an increased mortality rate, including sudden unexpected death in epilepsy (SUDEP). Approximately 90% of patients carry a heterozygous loss-of-function mutation in the SCN1A gene, which encodes a voltage-gated sodium ion channel, Na V 1.1. The Na V 1.1 channel is expressed in the brain and at a lower level, in the heart. Previous studies have identified a long non-coding RNA (lncRNA) which specifically downregulates SCN1A gene expression. This natural antisense transcript (NAT) can be modulated by AntagoNATs, small synthetic oligonucleotides developed to inhibit NAT function. In a DS mouse model, AntagoNATs were shown to modulate Scn1a expression by targeting the Scn1a NAT, improving seizure frequency after repeated administration. Here, we have developed novel AntagoNATs and incorporated these into a clinically relevant adeno-associated virus serotype 9 (AAV9) gene therapy vector, to test in a DS mouse model ( Scn1a +/- ) and provide a one-off treatment approach. Eighteen AntagoNATs were tested in vitro ; from the best performing candidates, we selected two AntagoNAT sequences (K & H) for in vivo testing as they had the highest homology (90%) to human SCN1A NAT. We administered both vectors to newborn Scn1a +/- mice via intracerebroventricular (ICV) and intravenous (IV) injection to target the brain and heart. AAV9-AntagoNAT-H significantly increased survival, decreased febrile seizures and reduced spontaneous seizure frequency compared to the PBS control group. When administered at P14 by ICV and IV injection, AAV9-AntagoNAT-H increased survival. In this proof-of-concept study, we have demonstrated for the first time the delivery of AntagoNAT technology via an AAV9 vector and thus offering the possibility of a one-time treatment for DS patients.
Open AccessAAV9-mediated targeting of natural antisense transcript as a novel treatment for Dravet Syndrome
Dravet syndrome (DS) is a severe childhood onset developmental and epileptic encephalopathy which leads to life-long disability. Symptoms usually manifest in the first year of life and include prolonged severe seizures, developmental delay and severe intellectual disability. DS patients have an increased mortality rate, including sudden unexpected death in epilepsy (SUDEP). Approximately 90% of patients carry a heterozygous loss-of-function mutation in the SCN1A gene, which encodes a voltage-gated sodium ion channel, Na V 1.1. The Na V 1.1 channel is expressed in the brain and at a lower level, in the heart. Previous studies have identified a long non-coding RNA (lncRNA) which specifically downregulates SCN1A gene expression. This natural antisense transcript (NAT) can be modulated by AntagoNATs, small synthetic oligonucleotides developed to inhibit NAT function. In a DS mouse model, AntagoNATs were shown to modulate Scn1a expression by targeting the Scn1a NAT, improving seizure frequency after repeated administration. Here, we have developed novel AntagoNATs and incorporated these into a clinically relevant adeno-associated virus serotype 9 (AAV9) gene therapy vector, to test in a DS mouse model ( Scn1a +/- ) and provide a one-off treatment approach. Eighteen AntagoNATs were tested in vitro ; from the best performing candidates, we selected two AntagoNAT sequences (K & H) for in vivo testing as they had the highest homology (90%) to human SCN1A NAT. We administered both vectors to newborn Scn1a +/- mice via intracerebroventricular (ICV) and intravenous (IV) injection to target the brain and heart. AAV9-AntagoNAT-H significantly increased survival, decreased febrile seizures and reduced spontaneous seizure frequency compared to the PBS control group. When administered at P14 by ICV and IV injection, AAV9-AntagoNAT-H increased survival. In this proof-of-concept study, we have demonstrated for the first time the delivery of AntagoNAT technology via an AAV9 vector and thus offering the possibility of a one-time treatment for DS patients.
- Open Access
- 13 September 2024
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 10 (1) , 1
Author Correction: Developmental and epileptic encephalopathies
- 13 September 2024
- Published by Springer Nature in Nature Reviews Disease Primers
- Vol. 10 (1) , 1
Open AccessAuthor Correction: Developmental and epileptic encephalopathies